Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.
- Conditions
- Fibrosis, LiverCirrhosis, Liver
- Interventions
- Registration Number
- NCT06293378
- Brief Summary
This is a controlled, observational clinical study initiated by investigators to investigate the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis. Four cohorts were planned: primary biliary cirrhosis, hepatitis B and C cirrhosis, and alcoholic cirrhosis. The four groups were divided into experimental group and control group, and the experimental group: each group of patients was orally treated sulfasalazine for 12 months, taken three times a day, each time taking 0.5g. The control group did not take sulfasalazine. After 12 months, Observe changes in patients' biochemical and imaging indicators, liver stiffness values, fecal microbiota, and metabolites before and after the use of sulfasalazine.
- Detailed Description
This study is a controlled and observational clinical study initiated by the investigators to study the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis, and to observe changes in patients' biochemical and imaging indicators, liver stiffness values, fecal microbiota, and metabolites before and after the use of sulfasalazine.
Four cohorts were planned to be included in this study:
Cohort A: Differences in cirrhosis changes with the addition of sulfasalazine to UDCA in PBC patients with an inadequate response to UDCA and treatment-naïve PBC patients.
Cohort B: Differences in changes in cirrhosis in patients with viral hepatitis B cirrhosis compared with the addition of sulfasalazine to antiviral (if possible, the same antiviral) therapy.
Cohort C: Differences in changes in cirrhosis in patients with viral hepatitis C cirrhosis compared with the addition of sulfasalazine to antiviral (if possible, the same antiviral) therapy.
Cohort D: Differences in differences in changes in cirrhosis compared with sulfasalazine in patients with alcoholic hepatitis cirrhosis.
Treatment options:
1. Patients with PBC who did not respond adequately to UDCA: 30 patients with poor response to treated PBC continued to take UDCA, 30 patients with poor response to treated PBC received UDCA+SASP (0.5 g orally three times daily), and 30 patients with poor response received SASP (0.5 g orally three times daily) for 12 months and were followed up for 12 months.
Treatment-naïve PBC patients: 30 treatment-naïve PBC patients took UDCA, and 30 treatment-naïve PBC patients took UDCA+SASP (0.5 g orally three times a day) for 12 months and followed up for 12 months.
2. Treatment group of hepatitis B (hepatitis C) viral liver cirrhosis: 60 patients with hepatitis B (hepatitis C) viral cirrhosis were collected (using the same dose of antiviral drugs), 30 patients with hepatitis B (hepatitis C) viral cirrhosis took antiviral drugs, and 30 patients with hepatitis B (hepatitis C) virus cirrhosis were treated with sulfasalazine (0.5g three times a day) on the basis of taking antiviral drugs, and follow-up observation was observed for 12 months.
3. Treatment group of alcoholic hepatitis cirrhosis: 60 patients with alcoholic cirrhosis were collected, 30 patients with alcoholic cirrhosis did not take antifibrotic drugs, 30 cases of alcoholic cirrhosis took sulfasalazine (0.5g three times a day), and follow-up observation was observed for 12 months.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 330
- Sign the informed consent form before the trial and be able to complete the study in accordance with the requirements of the trial protocol;
- The age is 18~70 years old (including boundary value), the weight of male subjects is not less than 45 kg, and the weight of female subjects is not less than 40 kg. Body mass index (BMI) in the range of 18~32kg/m2 (including critical value);
- Enrolled patients also need to meet:
A:Patients with PBC cirrhosis PBC patients who have been treated and show an inadequate response to UDCA：(1) according to the biochemical response criteria for 2021 PBC, Enrolled patients need to meet the criteria of ALP ≥1.67 × ULN as a poor biochemical response to UDCA after 12 months of UDCA treatment; (2) meeting the diagnostic criteria for primary cholangitis (PBC) , i.e. meeting at least two of the following criteria: 1.indicators of cholestasis such as elevated Alkaline phosphatase; 2.Anti-mitochondrial antibody AMA or AMA-m2 positive, or if AMA negative, PBC-specific antibodies (anti-GP210 Andor anti-SP100) positive .3 liver biopsy consistent with PBC; Patients with newly diagnosed primary cholangitis (PBC-RRB- met the diagnostic criteria of at least two of the following): 1.indicators of cholestasis such as elevated Alkaline phosphatase; 2.Anti-mitochondrial antibody AMA or AMA-m2 positive, or if AMA negative, PBC-specific antibodies (anti-GP210 Andor anti-SP100) positive 3. liver biopsy consistent with PBC; B:Patients with hepatitis B cirrhosis Diagnosis of hepatitis B cirrhosis based on clinical history, histology or imaging.
C:Patients with hepatitis C cirrhosis Diagnosis of hepatitis C cirrhosis based on clinical history, histology or imaging.
D:Alcoholic hepatitis cirrhosis Diagnosis of alcoholic cirrhosis based on clinical history, histology, or imaging.
- Those who have a history of allergies in the past, or the investigator suspects that they are allergic to the active ingredients of the drug or their excipients under study;
- Allergy to sulfasalazine and its metabolites, sulfonamides or salicylic acid;
- Patients with intestinal obstruction or urinary tract obstruction;
- Patients with porphyria, such as sulfonamides, have been reported to cause acute attacks.
- Acute and chronic liver disease with clinical significance caused by infections other than HBV, HCV, PBC, and alcoholic liver disease;
- Primary liver cancer; alpha-fetoprotein (AFP) greater than 50 ug/L or imaging suggests malignant liver mass; Those with other malignancies or a history of other malignancies in the 5 years prior to screening (except for complete remission of malignant tumors after treatment and no additional medical or surgical intervention within 3 years prior to screening);
- The investigator judged that there is impaired gastrointestinal function or gastrointestinal diseases that may affect the absorption of oral drugs, such as severe gastric ulcer, erosive gastritis, partial gastrectomy, and persistent >Grade 2 gastrointestinal symptoms (e.g., nausea, vomiting, or diarrhoea);
- Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, psychiatric, neurological, renal and other systems;
- Those who have had major trauma or undergone major surgery within 3 months before screening; or those who plan to undergo surgery during the study;
- Donated blood or lost blood ≥ 400mL within 3 months before screening, or received blood transfusion; or ≥ blood donation or blood loss within 1 month prior to screening 200mL；
- Those who are positive for AIDS antigen/antibody, positive for Treponema pallidum antibody and positive RPR test;
- History of drug dependence or drug abuse within 1 year prior to screening;
- Participate in clinical trials of other investigational drugs or medical devices within 3 months before screening, and take experimental drugs or use them Those who have medical devices;
- Those who have a positive pregnancy test during lactation or screening, or who have fertility requirements in the past two years;
- Subjects who the investigator believes have other factors that are not suitable to participate in this trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort A：Patients with PBC were treated with sulfasalazine Sulfasalazine enteric-coated tablets PBC treatment group: 1. PBC patients with poor response to UDCA after treatment: 30 patients continued to take UDCA 13-15mg/kg , 30 patients took UDCA 13-15mg/kg +SASP (0.5g orally three times a day), 30 patients took SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected. 2. Newly treated PBC patients: 30 patients took UDCA 13-15mg/kg and 30 patients took UDCA 13-15mg/kg +SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected. Cohort B：Patients with HBV were treated with sulfasalazine Sulfasalazine enteric-coated tablets Cohort B: 60 cases with hepatitis B cirrhosis were collected , 30 cases continued the current treatment(people with hepatitis B cirrhosis continue to take antivirals), and 30 patients were taking sulfasalazine for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected. Cohort C：Patients with HCV were treated with sulfasalazine Sulfasalazine enteric-coated tablets Cohort C: 60 cases with hepatitis C cirrhosis were collected，30 cases continued the current treatment(people with hepatitis C cirrhosis continue to take antivirals), and30 patients were taking sulfasalazine for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected. Cohort D：Patients with alcoholic liver fibrosis/cirrhosis were treated with sulfasalazine Sulfasalazine enteric-coated tablets 60 cases with alcoholic cirrhosis were collected , 30 cases continued the current treatment and 30 patients were taking sulfasalazine for 12 months of follow-up observation. During 12 months of treatment at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
- Primary Outcome Measures
Name Time Method Hepatic fibrosis baseline，1,3,6,9,12 months after treatment and 1 month after the end of treatment. The changes of liver fibrosis
Serum alkaline phosphatase (ALP) baseline,1,3,6,9,12 months after treatment and 1 month after the end of treatment. Serum alkaline phosphatase (ALP) level
Serum γ-glutamyl transpeptidase (GGT) baseline,1,3,6,9,12 months after treatment and 1 month after the end of treatment. Serum γ-glutamyl transpeptidase (GGT) level
Serum bilirubin baseline,1,3,6,9,12 months after treatment and 1 month after the end of treatment. Serum bilirubin level
Serum bile acids baseline,1,3,6,9,12 months after treatment and 1 month after the end of treatment. Serum bile acids level
Serum aspartate aminotransferase(AST) baseline,1,3,6,9,12 months after treatment and 1 month after the end of treatment. Serum aspartate aminotransferase(AST) level
Serum alanine aminotransferase (ALT) baseline,1,3,6,9,12 months after treatment and 1 month after the end of treatment. Serum alanine aminotransferase (ALT) level
- Secondary Outcome Measures
Name Time Method The gut microbiota and metabolites. baseline,1,3,6,9,12 months after treatment and 1 month after the end of treatment. The levels of changes in gut microbiota and metabolites.
Trial Locations
- Locations (2)
Chongqing Medical University
🇨🇳Chongqing, Chongqing, China
Chongqing
🇨🇳Chongqing, Chongqing, China